Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclosporine
Drug ID BADD_D00551
Description Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_.[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Indications and Usage Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy[L3002] and to prevent or treat graft-versus-host disease (GVHD).[L11097] Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone.[L3734] It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.[L3734] The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca.[L11097] In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.[L11097] A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.[L34694] Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.[A139,A174085,A189393,A189396,A189399]
Marketing Status approved; investigational; vet_approved
ATC Code S01XA18; L04AD01
DrugBank ID DB00091
KEGG ID D00184
MeSH ID D016572
PubChem ID 5280754
TTD Drug ID D0O3YF
NDC Product Code 10888-5040; 11014-0033; 11014-0034; 11014-0041; 51927-0160; 55361-0025; 55361-0023; 23155-838; 0172-7313; 64380-127; 64380-128; 68084-921; 51927-3196; 55486-1567; 55486-1604; 55500-0009; 0093-9020; 51862-460; 60505-0134; 64380-129; 65086-001; 0574-0866; 47848-004; 51552-0663; 59573-0001; 66507-0001; 0074-3108; 0078-0241; 23155-837; 23155-839; 47335-506; 60505-0133; 0378-8760; 65897-3008; 0078-0110; 60505-4630; 60505-4632; 63629-8640; 65897-1008; 0078-0246; 0078-0274; 0093-9019; 68084-879; 11014-0040; 51927-0213; 55361-0022; 55361-0026; 68254-2501; 0078-0248; 47335-507; 60505-4631; 60505-6202; 68180-214; 10888-5041; 52928-005; 52972-0027; 55486-1602; 10702-808; 68254-0008; 0074-3109; 0074-7269; 0078-0109; 0078-0240; 0023-5301; 0074-5503; 51862-458; 55486-1603; 0093-9018; 0023-9163
UNII 83HN0GTJ6D
Synonyms Cyclosporine | Cyclosporine A | Cyclosporin A | Ciclosporin | Cyclosporin | Neoral | Sandimmun Neoral | CyA-NOF | CyA NOF | Sandimmune | Sandimmun | CsA-Neoral | CsA Neoral | CsANeoral | OL 27-400 | OL 27 400 | OL 27400
Chemical Information
Molecular Formula C62H111N11O12
CAS Registry Number 59865-13-3
SMILES CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C (C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C C(C)C)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glaucoma06.03.01.0020.000409%
Glomerulonephritis membranous20.05.01.0070.000221%Not Available
Glossitis07.14.01.001--Not Available
Goitre05.02.01.001; 14.11.01.008--Not Available
Gout15.01.06.001; 14.09.01.0010.000652%Not Available
Graft versus host disease12.02.09.001; 10.02.01.0270.000829%Not Available
Granulocytopenia01.02.03.0030.000166%Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematuria21.10.01.018; 20.02.01.006; 24.07.01.047--
Haemoglobin13.01.05.018--Not Available
Haemolysis01.06.04.0020.000221%
Haemolytic anaemia01.06.03.0020.000387%Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.0010.000166%
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhage subcutaneous24.07.06.010; 23.06.07.0020.000221%Not Available
Hair growth abnormal23.02.06.0060.001370%Not Available
Hallucination, visual19.10.04.007--Not Available
Headache17.14.01.001--
Heart sounds abnormal13.14.01.002--Not Available
Hemiparesis17.01.04.001--
Hepatic cirrhosis09.01.04.0010.000387%Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.001326%Not Available
Hepatic pain09.01.05.005--
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.0080.000387%Not Available
Hepatorenal failure09.01.03.008; 20.01.03.013--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hernia08.01.04.0010.000608%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 28 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene